Cost Benefit Analysis of Herceptin

[Joe]

Are you worth keeping alive? I recall Lani posted something similar a few months back, but this one is a win for us:

http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCR D&vmview=abst_detail_view&confID=52&abstractID=40418


Regards
Joe

[Joanne S]

This was a study done in Brazil:

Conclusion: This cost-effectiveness analysis suggests that trastuzumab in adjuvant therapy for patients with early breast cancer HER-2 positive brings important clinical benefits and in addition is a cost-effective alternative in Brazil.